Search bioRxiv⌕ Search

Biology subjects

Rebadulla, K.

Publications and source records attributed to Rebadulla, K..

2 recordsLinked to original sources

Flux analysis resolves distinct brain uptake and clearance of TfR- and CD98hc-targeting large molecules

Advances in large-molecule delivery across the blood-brain barrier (BBB) by targeting receptors such as transferrin receptor (TfR) or CD98 heavy chain (CD98hc) are shifting the focus from restricted parenchymal access toward brain exposure profiles tailored to therapeutic needs. However, brain concentrations offer only partial insight into delivery mechanisms, as they reflect the net balance of two dynamic processes: flux of molecules entering and leaving the brain, here termed brain uptake and brain clearance, respectively. Here, we establish a generalizable experimental and mathematical modeling framework to resolve these opposing fluxes and demonstrate its application using pharmacokinetic (PK) data from Fc-engineered antibody transport vehicles (ATVs) targeting TfR or CD98hc in humanized knock-in mouse models. First, to directly estimate brain clearance, we engineered anti-ATV antibodies that selectively bind the TV patch to block receptor-mediated brain uptake in vivo. Integrating these measurements with a mechanistic PK model, we then reconstructed brain fluxes of ATV molecules over time across a broad range of receptor affinities. Results demonstrated that TfR-targeting promotes rapid, affinity-dependent brain uptake accompanied by comparatively rapid brain clearance, whereas CD98hc-targeting results in slower brain uptake and prolonged retention. Extending this framework to dual TfR/CD98hc-targeting ATVs suggested that higher observed brain exposure relative to single-receptor formats does not necessarily translate to greater brain delivery: increased exposure was predicted to arise primarily from reduced brain clearance, associated with CD98hc-mediated retention, rather than enhanced uptake through dual-receptor engagement. Together, these results establish a quantitative basis for resolving brain fluxes and engineering brain-targeted biologics for desired therapeutic outcomes.

systems biology↗

DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response

The integrated stress response (ISR) is a conserved pathway in eukaryotic cells that is activated in response to multiple sources of cellular stress. Although acute activation of this pathway restores cellular homeostasis, intense or prolonged ISR activation perturbs cell function and may contribute to neurodegeneration. DNL343 is an investigational CNS-penetrant small molecule ISR inhibitor designed to activate the eukaryotic initiation factor 2B (eIF2B) and suppress aberrant ISR activation. DNL343 reduced CNS ISR activity and neurodegeneration in a dose-dependent manner in two established in vivo models - the optic nerve crush injury and an eIF2B loss of function (LOF) mutant - demonstrating neuroprotection in both and preventing motor dysfunction in the LOF mutant mouse. Treatment with DNL343 at a late stage of disease in the LOF model reversed elevation in plasma biomarkers of neuroinflammation and neurodegeneration and prevented premature mortality. Several proteins and metabolites that are dysregulated in the LOF mouse brains were normalized by DNL343 treatment, and this response is detectable in human biofluids. Several of these biomarkers show differential levels in CSF and plasma from patients with vanishing white matter disease (VWMD), a neurodegenerative disease that is driven by eIF2B LOF and chronic ISR activation, supporting their potential translational relevance. This study demonstrates that DNL343 is a brain penetrant ISR inhibitor capable of attenuating neurodegeneration in mouse models and identifies several biomarker candidates that may be used to assess treatment responses in the clinic.

neuroscience↗